Advertisement

Alpha-Defensin Offers Limited Utility in Work-Up Prior to Reimplantation in Chronic Periprosthetic Joint Infection in Total Joint Arthroplasty Patients

      Abstract

      Background

      Alpha-defensin (AD) is a synovial biomarker included in the 2018 consensus criteria for diagnosing periprosthetic joint infection (PJI). Its value in assessing eradication of infection prior to second stage reimplantation is unclear. The purpose of this study was to evaluate the impact of AD on eligibility for reimplantation following resection for chronic PJI.

      Methods

      This study included patients who previously underwent resection arthroplasty for PJI. Synovial fluid aspirated from 87 patients was retrospectively reviewed. All patients completed a 6-week course of intravenous antibiotics and an appropriate drug holiday. Synovial white blood cell count, percentage neutrophils, and culture from the AD immunoassay laboratory were reviewed with serum erythrocyte sedimentation rate and C-reactive protein values from our institution. A modified version of the 2018 consensus criteria was used, including white blood cell count, percentage neutrophils, erythrocyte sedimentation rate, and C-reactive protein. AD was then added to determine if it changed diagnosis or clinical management.

      Results

      Four patients were categorized as “infected” (score >6), none exhibited a positive AD or positive culture. Sixty eight patients were diagnosed as “possibly infected” (score 2 to 5), none had a positive AD, and one had a positive culture (Cutibacterium acnes). AD did not change the diagnosis from “possibly infected” to “infected” in any case or alter treatment plans. Fifteen patients had a score of <2 (not infected) and none had a positive AD.

      Conclusion

      The routine use of AD in the work-up prior to a second-stage arthroplasty procedure for PJI may not be warranted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Arthroplasty
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Springer B.D.
        • Cahue S.
        • Etkin C.D.
        • Lewallen D.G.
        • McGrory B.J.
        Infection burden in total hip and knee arthroplasties: an international registry-based perspective.
        Arthroplast Today. 2017; 3: 137-140https://doi.org/10.1016/j.artd.2017.05.003
        • Frangiamore S.J.
        • Gajewski N.D.
        • Saleh A.
        • Farias-Kovac M.
        • Barsoum W.K.
        • Higuera C.A.
        α-Defensin accuracy to diagnose periprosthetic joint infection-best available test?.
        J Arthroplasty. 2016; 31: 456-460https://doi.org/10.1016/j.arth.2015.09.035
        • Kelly M.P.
        • Darrith B.
        • Hannon C.P.
        • Nam D.
        • Courtney P.M.
        • Della Valle C.J.
        Synovial fluid alpha-defensin is an adjunctive tool in the equivocal diagnosis of periprosthetic joint infection.
        J Arthroplasty. 2018; 33: 3537-3540https://doi.org/10.1016/j.arth.2018.06.026
        • Deirmengian C.
        • Kardos K.
        • Kilmartin P.
        • Cameron A.
        • Schiller K.
        • Parvizi J.
        Combined measurement of synovial fluid a-defensin and C-reactive protein levels: highly accurate for diagnosing periprosthetic joint infection.
        J Bone Joint Surg Am. 2014; 96: 1439-1445https://doi.org/10.2106/JBJS.M.01316
        • Kleeman-Forsthuber L.T.
        • Dennis D.A.
        • Brady A.C.
        • Pollet A.K.
        • Johnson R.M.
        • Jennings J.M.
        Alpha-defensin is not superior to traditional diagnostic methods for detection of periprosthetic joint infection in total hip arthroplasty and total knee arthroplasty patients.
        J Arthroplasty. 2021; 36: 2144-2149https://doi.org/10.1016/j.arth.2021.01.036
        • Parvizi J.
        • Tan T.L.
        • Goswami K.
        • Higuera C.
        • Della Valle C.
        • Chen A.F.
        • et al.
        The 2018 definition of periprosthetic hip and knee infection: an evidence-based and validated criteria.
        J Arthroplasty. 2018; 33: 1309-1314.e2https://doi.org/10.1016/j.arth.2018.02.078
        • Zmistowski B.
        • Tetreault M.W.
        • Alijanipour P.
        • Chen A.F.
        • Della Valle C.J.
        • Parvizi J.
        Recurrent periprosthetic joint infection: persistent or new infection?.
        J Arthroplasty. 2013; 28: 1486-1489https://doi.org/10.1016/j.arth.2013.02.021
        • Mortazavi S.M.J.
        • Vegari D.
        • Ho A.
        • Zmistowski B.
        • Parvizi J.
        Two-stage exchange arthroplasty for infected total knee arthroplasty: predictors of failure.
        Clin Orthop Relat Res. 2011; 469: 3049-3054https://doi.org/10.1007/s11999-011-2030-8
        • Samuel L.T.
        • Sultan A.A.
        • Kheir M.
        • Villa J.
        • Patel P.
        • Parvizi J.
        • et al.
        Positive alpha-defensin at reimplantation of a two-stage revision arthroplasty is not associated with infection at 1 year.
        Clin Orthop Relat Res. 2019; 477: 1615-1621https://doi.org/10.1097/CORR.0000000000000620
        • Kheir M.M.
        • Ackerman C.T.
        • Tan T.L.
        • Benazzo A.
        • Tischler E.H.
        • Parvizi J.
        Leukocyte esterase strip test can predict subsequent failure following reimplantation in patients with periprosthetic joint infection.
        J Arthroplasty. 2017; 32: 1976-1979https://doi.org/10.1016/j.arth.2017.01.031
        • Lee Y.S.
        • Koo K.-H.
        • Kim H.J.
        • Tian S.
        • Kim T.-Y.
        • Maltenfort M.G.
        • et al.
        Synovial fluid biomarkers for the diagnosis of periprosthetic joint infection.
        J Bone Joint Surg Am. 2017; 99: 2077-2084https://doi.org/10.2106/jbjs.17.00123
        • Ganz T.
        • Selsted M.E.
        • Szklarek D.
        • Harwig S.S.
        • Daher K.
        • Bainton D.F.
        • et al.
        Defensins. Natural peptide antibiotics of human neutrophils.
        J Clin Invest. 1985; 76: 1427-1435https://doi.org/10.1172/JCI112120
        • Deirmengian C.
        • Kardos K.
        • Kilmartin P.
        • Gulati S.
        • Citrano P.
        • Booth R.E.
        The alpha-defensin test for periprosthetic joint infection responds to a wide spectrum of organisms.
        Clin Orthop Relat Res. 2015; 473: 2229-2235https://doi.org/10.1007/s11999-015-4152-x
        • Wyatt M.C.
        • Beswick A.D.
        • Kunutsor S.K.
        • Wilson M.J.
        • Whitehouse M.R.
        • Blom A.W.
        The alpha-defensin immunoassay and leukocyte esterase colorimetric strip test for the diagnosis of periprosthetic infection a systematic review and meta-analysis.
        J Bone Joint Surg Am. 2016; 98: 992-1000https://doi.org/10.2106/JBJS.15.01142
        • Deirmengian C.
        • Kardos K.
        • Kilmartin P.
        • Cameron A.
        • Schiller K.
        • Booth R.E.
        • et al.
        The alpha-defensin test for periprosthetic joint infection outperforms the leukocyte esterase test strip.
        Clin Orthop Relat Res. 2015; 473: 198-203https://doi.org/10.1007/s11999-014-3722-7
        • Stone W.Z.
        • Gray C.F.
        • Parvataneni H.K.
        • Al-Rashid M.
        • Vlasak R.G.
        • Horodyski M.B.
        • et al.
        Clinical evaluation of synovial alpha defensin and synovial C-reactive protein in the diagnosis of periprosthetic joint infection.
        J Bone Joint Surg Am. 2018; 100: 1184-1190https://doi.org/10.2106/JBJS.17.00556
        • Kleeman-Forsthuber L.T.
        • Johnson R.M.
        • Brady A.C.
        • Pollet A.K.
        • Dennis D.A.
        • Jennings J.M.
        Alpha-defensin offers limited utility in routine workup of periprosthetic joint infection.
        J Arthroplasty. 2020; 36: 1746-1752https://doi.org/10.1016/j.arth.2020.12.018
        • Carender C.N.
        • DeMik D.E.
        • Otero J.E.
        • Noiseux N.O.
        • Brown T.S.
        • Bedard N.A.
        What is the clinical utility of synovial alpha defensin testing of antibiotic spacers before reimplantation?.
        J Arthroplasty. 2021; 36: 2150-2157https://doi.org/10.1016/j.arth.2021.02.001
        • Bielefeld C.
        • Engler H.
        • Jäger M.
        • Wegner A.
        • Wassenaar D.
        • Busch A.
        Synovial alpha-defensin at reimplantation in two-stage revision arthroplasty to rule out persistent infection.
        In Vivo. 2021; 35: 1073-1081https://doi.org/10.21873/INVIVO.12352
        • Suen K.
        • Keeka M.
        • Ailabouni R.
        • Tran P.
        Synovasure ‘quick test’ is not as accurate as the laboratory-based α-defensin immunoassay.
        Bone Joint J. 2018; 100-B: 66-72https://doi.org/10.1302/0301-620x.100b1.bjj-2017-0630.r1
        • Amanatullah D.F.
        • Cheng R.Z.
        • Huddleston J.I.
        • Maloney W.J.
        • Finlay A.K.
        • Kappagoda S.
        • et al.
        The routine use of synovial alpha-defensin is not necessary.
        Bone Joint J. 2020; 102-B: 593-599https://doi.org/10.1302/0301-620X.102B5.BJJ-2019-0473.R3
        • Parvizi J.
        • Gehrke T.
        • Chen A.F.
        Proceedings of the international consensus on periprosthetic joint infection.
        Bone Joint J. 2013; 95 B: 1450-1452https://doi.org/10.1302/0301-620X.95B11.33135
        • de Saint Vincent B.
        • Migaud H.
        • Senneville E.
        • Loiez C.
        • Pasquier G.
        • Girard J.
        • et al.
        Diagnostic accuracy of the alpha defensin lateral flow device (Synovasure) for periprosthetic infections in microbiologically complex situations: a study of 42 cases in a French referral centre.
        Orthop Traumatol Surg Res. 2018; 104: 427-431https://doi.org/10.1016/j.otsr.2018.01.018
        • Bian T.
        • Shao H.
        • Zhou Y.
        • Huang Y.
        • Song Y.
        Tests for predicting reimplantation success of two-stage revision for periprosthetic joint infection: a systematic review and meta-analysis.
        Orthop Traumatol Surg Res. 2018; 104: 1115-1123https://doi.org/10.1016/j.otsr.2018.03.017
        • Zmistowski B.M.
        • Clyde C.T.
        • Ghanem E.S.
        • Gotoff J.R.
        • Deirmengian C.A.
        • Parvizi J.
        Utility of synovial white blood cell count and differential before reimplantation surgery.
        J Arthroplasty. 2017; 32: 2820-2824https://doi.org/10.1016/j.arth.2017.03.068
        • Cooper H.J.
        • Della Valle C.J.
        The two-stage standard in revision total hip replacement.
        Bone Joint J. 2013; 95-B: 84-87https://doi.org/10.1302/0301-620X.95B11.32906
        • Stone W.Z.
        • Gray C.F.
        • Parvataneni H.K.
        • Prieto H.A.
        Clinical evaluation of alpha defensin test following staged treatment of prosthetic joint infections.
        J Arthroplasty. 2019; 34: 1446-1451https://doi.org/10.1016/j.arth.2019.03.019
        • Saleh A.
        • Ramanathan D.
        • Siqueira M.B.P.
        • Klika A.K.
        • Barsoum W.K.
        • Rueda C.A.H.
        The diagnostic utility of synovial fluid markers in periprosthetic joint infection.
        J Am Acad Orthop Surg. 2017; 25: 763-772https://doi.org/10.5435/jaaos-d-16-00548
        • Bingham J.
        • Clarke H.
        • Spangehl M.
        • Schwartz A.
        • Beauchamp C.
        • Goldberg B.
        The alpha defensin-1 biomarker assay can be used to evaluate the potentially infected total joint arthroplasty.
        Clin Orthop Relat Res. 2014; 472: 4006-4009https://doi.org/10.1007/s11999-014-3900-7